ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2014
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.Blood advances · 2020Trial
- A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.Journal of clinical and experimental hematopathology : JCEH · 2017Trial
- Trial
- Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy.Cell reports. Medicine · 2025Article
- Signaling pathways in brain tumors and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.BMC cancer · 2022Article
- Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review.Cancers · 2021Article
- Case Report: Identification of Potential Prognosis-RelatedFrontiers in endocrinology · 2021Article
- Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.Oncology letters · 2020Article
- High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.Cancer medicine · 2019Article
- Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.Oncotarget · 2018Article
- Advances in the treatment of newly diagnosed primary central nervous system lymphomas.Blood research · 2017Review
- Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.Oncotarget · 2017Article
- Primary central nervous system lymphoma: essential points in diagnosis and management.Medical oncology (Northwood, London, England) · 2017Review
- Primary central nervous system lymphoma.Hematology. American Society of Hematology. Education Program · 2016Review
- The Challenge of Primary Central Nervous System Lymphoma.Hematology/oncology clinics of North America · 2016Review
- Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.Oncotarget · 2016Article
- Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.International journal of molecular sciences · 2016Article
- [High-dose pemetrexed in combination with temolozomide for the treatment of newly diagnosed primary central nervous system lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.Journal of neuro-oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundWhile there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. PATIENTS AND
methodsWe reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology.
resultsWhile PCNSL tumors usually express a BCL6+, MUM1+ 'activated, germinal center' immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses.
conclusionsThere is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive side-effects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.